An interventional study of Laparoscopic Discoid or Double Discoid Excision and Laparoscopic Segmental Rectal Resection in Rectal Endometriosis and Deep Infiltrating Endometriosis (DIE), sponsored by Alexandria University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Alexandria University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Endometriosis with a site in Egypt — 5 open to participants now, 5 under way, none of them phase 3. Endometriosis · Egypt.
Among the 30 studies in Endometriosis with a site in Egypt, this one is the 2nd largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2026, is one of 17 with no phase, and was the 30th registered.
924 studies on the registry are indexed under Endometriosis; 269 are open to participants now.
Browse Endometriosis studies →5 of the 30 studies in Endometriosis with a site in Egypt are open now. Recruiting first, the newest first:
Benha University · Sites in Egypt
Ages 18–45 · Women only
Beni-Suef University · Sites in Egypt
Ages 18–45 · Women only
Cairo University · Sites in Egypt
Ages 20–40 · Women only · Healthy volunteers
Alexandria University · Sites in Egypt
Ages 18–50 · Women only · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 180 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 126 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 67 across 542 interventional studies indexed under Endometriosis.
Median enrollment 92 across the 25 interventional studies, 88 across the 5 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 30 have an industry lead sponsor. The 10 most frequent:
Alexandria University is the lead sponsor of 610 studies on the registry; 143 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Alexandria University has 2 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Endometriosis with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07592403Beni-Suef UniversityEfficacy of Pulsed Electromagnetic Field Therapy on Women With Endometriosis | 2027-01-20 |
| NCT07949136Alexandria UniversityDiscoid Excision Versus Segmental Resection for Rectal Endometriosis | 2027-04 |
| NCT07686783Benha UniversityOvarian Reserve After Laparoscopic Cystectomy for Endometriotic and Non-Endometriotic Cysts | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Endometriosis with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial will compare two types of surgery for endometriosis affecting the rectum, the lower part of the bowel. It will include 200 women aged 18 to 45 years who have symptoms and a single area of rectal endometriosis smaller than 5 cm. All participants must need surgery and be suitable for either procedure.
The main questions are:
Do the two procedures differ in the risk of bowel complications within 90 days after surgery?
How do the procedures affect bowel function, quality of life, and pain?
Participants will be assigned by chance to one of two groups:
Discoid or double discoid excision: The surgeon removes one or two overlapping discs of the affected bowel wall without removing an entire bowel segment.
Segmental resection: The surgeon removes the affected bowel segment and joins the remaining bowel ends.
Both procedures will be performed using keyhole surgery. Assignment will take place during surgery, after the surgeon confirms that either procedure is suitable.
Researchers will compare bowel complications, including leakage from the bowel closure, narrowing of the rectum, and abnormal connections between the bowel and nearby organs or tissues. Participants will complete questionnaires about quality of life and bowel function before surgery and at 6 and 12 months afterward. Researchers will also assess pain, recovery, and the need for further surgery. Follow-up will continue for up to 24 months to assess later symptoms and further treatment.
This prospective, single-center, parallel-group randomized controlled trial will compare bowel-preserving discoid or double discoid excision with segmental rectal resection for symptomatic rectal deep endometriosis. The study focuses on women with a single rectal nodule smaller than 5 cm for whom both surgical approaches are considered technically feasible.
The rationale is to determine whether removing only the affected portion of the rectal wall offers a different balance of postoperative bowel complications and functional outcomes compared with removal of the affected bowel segment. The discoid excision arm includes a double discoid technique when the lesion cannot be removed using a single stapler application.
Participants will provide written informed consent before surgery. Randomization will occur intraoperatively after laparoscopic assessment confirms nodule characteristics and eligibility for both procedures. A computer-generated sequence will allocate participants in a 1:1 ratio. Allocation will be concealed through a centralized online system accessed by an independent trial coordinator.
The discoid excision group will undergo laparoscopic mobilization of the rectum and full-thickness removal of the lesion using a circular stapler. Sequential double discoid excision will be used when required by lesion size. The segmental resection group will undergo laparoscopic removal of the affected bowel segment with a stapled colorectal anastomosis. Both groups will follow standardized protocols for bowel closure integrity testing, selective pelvic drainage, and indications for a diverting stoma. Conversion from the assigned technique will be permitted when intraoperative findings make it necessary for patient safety.
Surgeons and participants will not be blinded to treatment allocation. Postoperative outcome assessors, complication assessors, and the statistician performing the primary analysis will be blinded to allocation.
The primary comparison will assess the occurrence of the composite bowel complication outcome within 90 days after surgery. Longer-term assessments will examine bowel function, endometriosis-related quality of life, pain, symptom recurrence, and reintervention. Quality of life and bowel function will be measured using the Endometriosis Health Profile-30 questionnaire and the Low Anterior Resection Syndrome score.
The primary analysis will follow the intention-to-treat principle. Prespecified adjustment variables will include nodule size, circumferential involvement, and distance from the anal verge. Repeated questionnaire measurements will be analyzed using mixed-effects models. Treatment-effect estimates will be reported with 95% confidence intervals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo laparoscopic full-thickness discoid excision of the rectal endometriosis nodule using a circular stapler. When the nodule exceeds the capacity of a single stapler application, sequential double discoid excision will be performed using two circular staplers. The procedure will remove the affected rectal wall without segmental bowel resection.
Procedure: Laparoscopic Discoid or Double Discoid Excision
Participants will undergo laparoscopic resection of the bowel segment affected by rectal endometriosis, followed by a stapled end-to-end or end-to-side colorectal anastomosis. Mesorectal preservation close to the bowel wall will be used to limit disruption of the local blood supply.
Procedure: Laparoscopic Segmental Rectal Resection
Laparoscopic mobilization of the rectum followed by full-thickness excision of the endometriosis nodule using a circular stapler. Sequential double discoid excision using two circular staplers will be performed when required by nodule size. An intraoperative air leak test will assess staple-line integrity. Pelvic drainage and a diverting stoma will be used selectively according to protocolized indications.
Laparoscopic mobilization and resection of the affected bowel segment, followed by a stapled end-to-end or end-to-side colorectal anastomosis, with mesorectal preservation close to the bowel wall. An intraoperative air leak test will assess anastomotic integrity. Pelvic drainage and a diverting stoma will be used selectively according to protocolized indications.
Percentage of Participants With Major Bowel-Related Complications
Percentage of participants experiencing at least one of the following complications: anastomotic or staple-line leak, rectal stenosis, or rectovaginal or bowel fistula. Each participant will be counted once in the composite outcome, regardless of the number of qualifying complications. Complication severity will be graded using the Clavien-Dindo classification.
Time frame: Within 90 days after surgery
Percentage of Participants With Anastomotic or Staple-Line Leak
Percentage of participants developing leakage from the colorectal anastomosis or rectal staple line following the assigned surgical procedure. Complication severity will be graded using the Clavien-Dindo classification.
Time frame: Within 90 days and within 12 months after surgery
Percentage of Participants With Rectal Stenosis
Percentage of participants developing postoperative narrowing at the rectal excision or colorectal anastomosis site. Complication severity will be graded using the Clavien-Dindo classification.
Time frame: Within 90 days and within 12 months after surgery
Percentage of Participants With Rectovaginal or Bowel Fistula
Percentage of participants developing an abnormal communication between the rectum and vagina, or another postoperative bowel fistula. Complication severity will be graded using the Clavien-Dindo classification.
Time frame: Within 90 days and within 12 months after surgery
Endometriosis Health Profile-30 Domain Scores
Endometriosis-related quality of life assessed using the Endometriosis Health Profile-30 (EHP-30). The core questionnaire measures five domains: pain, control and powerlessness, emotional well-being, social support, and self-image. Each domain is scored separately from 0 to 100, with higher scores indicating worse health status. Domain scores will be compared between groups over time.
Time frame: Before surgery and at 6 and 12 months after surgery
Low Anterior Resection Syndrome Score
Bowel function assessed using the Low Anterior Resection Syndrome (LARS) score, which evaluates incontinence for flatus, incontinence for liquid stools, bowel movement frequency, clustering, and urgency. Total scores range from 0 to 42, with higher scores indicating worse bowel dysfunction. Categories are no LARS (0-20), minor LARS (21-29), and major LARS (30-42). Scores will be compared between groups over time.
Time frame: Before surgery and at 6 and 12 months after surgery
Operative Time
Duration of the surgical procedure, measured in minutes.
Time frame: During surgery
Estimated Intraoperative Blood Loss
Estimated volume of blood lost during the surgical procedure, measured in milliliters.
Time frame: During surgery
Postoperative Length of Hospital Stay
Number of days from the surgical procedure to discharge from the hospital.
Time frame: From surgery to discharge from the initial surgical hospitalization up to 1 week
Percentage of Participants Receiving a Diverting Stoma
Percentage of participants undergoing creation of a diverting stoma during the assigned surgical procedure.
Time frame: During surgery
Percentage of Participants With Recurrence of Endometriosis-Related Pain
Percentage of participants experiencing recurrence of endometriosis-related pain symptoms after initial postoperative improvement.
Time frame: At 12 and 24 months after surgery
Started Oct 2026 (actual). Primary completion is estimated for Apr 2027, 6 months after the start.
Of 199 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 6 months is below that.
Counting every sponsor, half of 214 studies reached it within 25 months; a quarter within 13 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.